Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Pulmatrix, Inc. Common Stock

PULM

Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.29 – $1.53
Volume 2,405
Market cap $5M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.86M
Price / earnings
—
Price / book
1.9×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.65×

Profitability

Earnings per share
-$1.10
Return on assets
-124.12%
Return on equity
-157.57%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.7×
Quick ratio
4.7×
Cash ratio
3.15×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3.91M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PULM, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$3K$366K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$3K$366K
Selling, general and administrative$1.04M$1.29M$911K$858K$1.53M$1.83M$1.95M$2.21M
Research and development$2K$3K-$3K$8K$14K$19K$6K$814K
Total operating expenses$1.05M$1.29M$908K$866K$1.55M$1.85M$4.57M$3.02M
Operating income-$1.05M-$1.29M-$908K-$866K-$1.55M-$1.85M-$4.57M-$2.66M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$1.04M-$1.17M-$928K-$877K-$1.55M-$1.81M-$1.99M-$2.59M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.04M-$1.17M-$928K-$877K-$1.55M-$1.81M-$1.99M-$2.59M
Net income attributable to common shareholders-$1.05M-$1.17M-$928K-$877K-$1.55M-$1.81M-$1.99M-$2.59M
EBITDA-$1.05M-$1.29M-$908K-$866K-$1.55M-$1.85M-$1.95M-$2.66M
Basic earnings per share-$0.29-$0.32-$0.25-$0.24-$0.42-$0.50-$0.54-$0.71
Diluted earnings per share-$0.29-$0.32-$0.25-$0.24-$0.42-$0.50-$0.54-$0.71

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Halper Sadeh LLC is Investigating Whether SLP, HUN, OLN, PULM are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The investigations concern whether shareholders are receiving fair consideration in these transactions, with concerns that insiders may benefit disproportionately and deal terms may prevent superior competing offers.

GlobeNewswire Inc.

Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum

Eos SENOLYTIX presented preclinical data for its lead candidate PTC-2105, a mitochondrial-targeted geropeptide showing improvements in body composition with lean mass gains and fat reduction without the muscle loss associated with GLP-1 therapies. The company also announced a merger agreement with Pulmatrix, Inc., expected to close in Q3 2026 under the new ticker symbol MTXL. Preclinical studies demonstrated extended survival in aged mice and prevention of age-related decline.

Zacks Investment Research

UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of -148.48% and 98.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 1, 20221-for-20reverse split
Feb 6, 20191-for-10reverse split